Disposition of 437 shares by Sandra Gurrola of Eterna Therapeutics subject to Rule 16b-3

ERNA Stock  USD 0.29  0.01  2.11%   
About 81 percent of all Eterna Therapeutics' investors are aggressively thinking of buying. The analysis of the overall investor sentiment regarding Eterna Therapeutics suggests that a fairly large number of traders are excited. The current market sentiment, together with Eterna Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Eterna Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Eterna Therapeutics Officer: Sr. Vp Of Finance. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Eterna insider trading alert for disposition of restricted stock units by Sandra Gurrola, Officer: Sr. Vp Of Finance, on 21st of June 2024. This event was filed by Eterna Therapeutics with SEC on 2024-06-21. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Eterna Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Eterna Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Eterna Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Eterna Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Eterna Therapeutics Fundamental Analysis

We analyze Eterna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

Eterna Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Eterna Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eterna Therapeutics stock to make a market-neutral strategy. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics with similar companies.

Peers

Eterna Therapeutics Related Equities

APLSApellis Pharmaceuticals   4.11   
0%
48.0%
ANNXAnnexon   3.35   
0%
39.0%
ZVSAZyVersa Therapeutics   2.86   
0%
33.0%
CGEMCullinan Oncology   1.63   
0%
19.0%
GPCRStructure Therapeutics   0.67   
0%
7.0%
RLAYRelay Therapeutics   0.31   
3.0%
0%
REVBRevelation Biosciences   1.15   
13.0%
0%
ZURAZura Bio   1.71   
20.0%
0%
ITOSIteos Therapeutics   2.00   
23.0%
0%
PALIPalisade Bio   3.61   
42.0%
0%
TCRXTscan Therapeutics   3.81   
45.0%
0%
DAWNDay One   5.08   
60.0%
0%
UNCYUnicycive Therapeutics   5.45   
64.0%
0%
ABOSAcumen Pharmaceuticals   5.47   
64.0%
0%
RNAZTranscode Therapeutics   5.56   
65.0%
0%
INZYInozyme Pharma   6.67   
79.0%
0%
PHIOPhio Pharmaceuticals   7.04   
83.0%
0%
XFORX4 Pharmaceuticals   7.50   
88.0%
0%
RCUSArcus Biosciences   7.71   
91.0%
0%
IMMXImmix Biopharma   8.43   
100.0%
0%

Complementary Tools for Eterna Stock analysis

When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal